The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer.
Xiuli TaoNing LiNing WuJie HeJianming YingShugeng GaoShuhang WangJie WangZhijie WangYun LingWei TangZewei ZhangPublished in: European journal of nuclear medicine and molecular imaging (2020)
18F-FDG PET-CT can predict MPR to neoadjuvant sintilimab in resectable non-small cell lung cancer.